It's scary losing blood. And bleeding inside the body somewhere along the esophagus, stomach and the upper small intestine can be even scarier. But blood transfusions can help, especially with certain methods.

Doctors have long debated the appropriate timing for a red blood cell transfusion. Is it better to wait until the last minute when patients are in the most need? Or should doctors be proactive and transfuse early? Which is safer?

Cancer in one person can behave very differently than it might in another person. That’s because each person’s genes are unique. So some new cancer treatments can target the individual’s unique genetic fingerprint. Scientists are exploring possible new targets in lymphoma.

Taking low-dose aspirin daily has been touted for years to lower the risk of heart attack and stroke. Some people show resistance to this therapy in blood tests, but why?

There has been a shortage of certain medications for about three years now. Particularly hard hit have been generic injectable drugs. The shortage of one medication has affected kids with cancer.

There has been lots of really good news about a rare blood cancer. Several new drugs have been approved to treat all stages of chronic myeloid leukemia ( CML ). There’s also work happening to go after the disease at deeper levels.

There is excellent news for people with mantle cell lymphoma, a rare blood cancer. An experimental drug is demonstrating impressive results in a phase II clinical trial. But this is a limited research study, and the product is not yet available.

When the World Trade Centers evaporated on 9/11, clouds of toxic chemicals were left in their wake. Researchers wanted to know the impact of these clouds on the health of rescue workers.

When blood has gone bad, patients turn normally to donors for help. But using undefined stem cells from other parts of the patient's body may help donors become more of a last-minute option in the future.

Folks living with two types of blood cancer have new choices as of today. The US Food and Drug Administration has approved Iclusig ( ponatinib ) to treat chronic myeloid leukemia ( CML ) and Philadelphia chromosome-positive acute lymphoblastic leukemia ( Ph + ALL).